Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.63 |
| ▸ | AR | P10275 | 8/20 | 0.63 |
| ▸ | BTK | Q06187 | 2/20 | 0.49 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.49 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | HPGDS | O60760 | 1/20 | 0.48 |
| ▸ | ITK | Q08881 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23171819 | 1.00 | CRBN (0.63) | CRBNARBTKIRAK1IRAK4 | |
| SCHEMBL25902388 | 0.95 | CRBN (0.63) | CRBNARBTKIRAK1IRAK4 | |
| SCHEMBL25902566 | 0.95 | CRBN (0.63) | CRBNARBTKIRAK1IRAK4 | |
| SCHEMBL24030050 | 0.92 | CRBN (0.55) | CRBNARBTKIRAK1IRAK4 | |
| SCHEMBL25899919 | 0.91 | CRBN (0.61) | CRBNARBTKIRAK1IRAK4 | |
| SCHEMBL24030221 | 0.91 | CRBN (0.55) | CRBNARBTKIRAK1IRAK4 | |
| SCHEMBL24031399 | 0.90 | CRBN (0.54) | CRBNARBTKDDB1ESR1 | |
| SCHEMBL25902377 | 0.90 | CRBN (0.64) | CRBNARDDB1HPGDS | |
| SCHEMBL23129054 | 0.89 | CRBN (0.55) | CRBNARBTKIRAK1IRAK4 | |
| SCHEMBL26808846 | 0.89 | CRBN (0.54) | CRBNARBTKDDB1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233690-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233690-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | AR, SHBG, CYP19A1 | CRBN 945/4885AR 1/4885BTK 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.